CerTest has released the new VIASURE SARS-CoV-2 Real Time PCR Detection Kit, designed for the specific identification and differentiation of the new coronavirus (SARS-CoV-2) in clinical samples from patients with signs and symptoms of being infected with the COVID-19.
Precisely, the symptoms of coronavirus include pneumonia with a high fever, dry cough, headache and difficulty breathing. With an incubation period from three to seven days, with a maximum of 14, transmission from person to person has been confirmed even in the incubation period from asymptomatic patients.
Other less common symptoms are sore throat, diarrhea and vomiting.
At the moment, CerTest has released two versions of the coronavirus diagnostic kit. The first one, monoplex, amplifies a fragment of the S gene of the virus. The second version, multiplex, amplifies and identifies fragments of the ORF1ab and N genes. The difference between the two versions is that the multiplex one identifies the sequences published by the Chinese Center for Disease Control and Prevention.
VIASURE Real Time PCR Detection kits is the CerTest brand that develops molecular biology assays to identify pathogens that cause infectious diseases by amplifying fragments of the DNA of the pathogen present in the patient sample.
Although the number of infections in China is declining, in the last days new cases of contagion are being registered in 40 other countries worldwide, with special attention to South Korea, Japan, Singapore, Iran, Thailand, Italy or Taiwan.
For more information on the use and operation of the new kit, contact the technical development team, through the CerTest website.
More information about VIASURE at https://www.certest.es/viasure/